SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.125    -0.875 (-43.75%)
Bid:
1.00
Ask:
1.25
Spread: 0.25 (25.00%)
Market Cap: £1.88m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

Director/PDMR Shareholding

18 Jun 2024 07:00

RNS Number : 8463S
BSF Enterprise PLC
18 June 2024
 

 

18 June 2024

BSF Enterprise PLC

("BSF" or the "Company")

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS

 

BSF (LSE: BSFA), (OTCQB: BSFAF), has received notification from its CFO, Graham Duncan, being a person discharging managerial responsibilities, of the purchase of shares as set out in the notification of dealing form here:

http://bsfenterprise.com/wp-content/uploads/2024/06/PDMR_Notification_00380329.pdf

 

 

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

 

BSF Enterprise PLC

 

 

Via SEC Newgate below

Geoff Baker - Executive Director

Che Connon - CEO & Director

 

 

Shard Capital (Broker)

Damon Heath

Isabella Pierre

0207 186 9000

0207 186 9927

 

SEC Newgate (Financial Communications)

Bob Huxford

Elisabeth Cowell

George Esmond

020 3757 6882

BSF@secnewgate.co.uk

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

 

Notes to Editors

 

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions to deliver sustainable materials and products across a variety of sectors. BSF Enterprise's core technology platform in industrial tissue engineering allows the manufacture at scale of lab-grown alternatives to animal and human tissues, helping deliver sustainable products and materials of the future. The Company's technologies have multiple applications across consumer and medical markets including lab-grown leather, cultivated meat, human corneas and in vitro animal models.

 

BSF owns 100% of pioneering UK-based tissue engineering companies 3D Bio-Tissues (3DBT), that successfully produced the UK's first high-quality cultivated meat and lab-grown skin from its laboratory and Kerato, a developer of lab-grown corneal replacement tissue for medical and research uses. In addition, it owns 100% of BSF Enterprise (Hong Kong) Limited which is actively supporting commercialisation of our technology in China and Asia.

 

BSF aims to deliver growth to shareholders through the continued commercialisation and expansion of the Groups IP, which has multiple applications, as well as through M&A. BSF aims to build a comprehensive portfolio in tissue engineering and related applications and license out IP to various stakeholders in the supply chain to enable manufacture at scale and achieve widespread market penetration.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFIFEERFITLIS
Date   Source Headline
12th Jun 20267:00 amRNSParis Auction Result
11th Jun 20267:00 amRNS£1 Million Convertible Loan Note
8th Jun 202611:59 amRNSShareholder meeting results
3rd Jun 20267:00 amRNSConditional Further Investment
2nd Jun 20268:50 amRNSTechnical White Paper on T-Rex Leather™
28th May 20267:00 amRNSAuction Update - May 2026
26th May 20267:00 amRNSStrategic Update May 2026
22nd May 20263:13 pmRNSPosting of Circular and Notice of General Meeting
5th May 20267:00 amRNST-Rex Leather™ handbag to be auctioned
17th Apr 202610:00 amRNSAdmission of Shares
13th Apr 20267:00 amRNSStrategic Shareholding Update
7th Apr 20267:00 amRNSWorld’s First T-Rex Leather Handbag Unveiled
2nd Apr 20267:00 amRNSWorld First T-Rex Leather™ Product
19th Mar 20267:00 amRNSSupply Agreement with SeaWith
17th Mar 20267:00 amRNSLGL Tanning Milestones
17th Mar 20267:00 amRNSLGL Tanning Milestones
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
3rd Mar 202611:00 amRNSResult of Annual General Meeting
27th Feb 20267:00 amRNSUpdate on Proposed Equity Fundraise
9th Feb 20267:00 amRNSNotice of 2026 AGM
3rd Feb 20265:14 pmRNSAnnual Financial Report - Correction
2nd Feb 20267:00 amRNSAnnual Financial Report
19th Jan 20267:00 amRNSKERATO LIMITED SIGNS WITH QUEBEC PSO GRANT
17th Dec 202511:08 amRNSResult of General Meeting
16th Dec 20257:00 amRNS3D Bio-Tissues Signs Supply Agreement with SeaWith
15th Dec 20257:00 amRNSChanges to timetable for proposed Equity Fundraise
5th Dec 20259:50 amRNS-RBSF Enterprise launches new Investor website
1st Dec 20257:02 amRNSProposed Equity Fundraise - Strategic Direction
1st Dec 20257:00 amRNSEquity Fundraise & Notice of General Meeting
29th Aug 202510:47 amRNSResignation of Chairman
10th Jul 20257:00 amRNSAgreement
25th Jun 20257:00 amRNSInterim 2025 Results
23rd May 20257:00 amRNS15p Warrants Amended
21st May 20257:00 amRNSLab-Grown Leather Ltd Progress
28th Apr 202510:01 amRNSStrategic Investment
25th Apr 20259:48 amRNSJoint Venture
13th Mar 20257:00 amRNS3DBT Lab Grown Leather Commercialization
6th Mar 20253:51 pmRNSPublication of a Prospectus
5th Mar 202512:10 pmRNSResult of Annual General Meeting
11th Feb 20258:21 amRNSExpected admission of shares - Replacement
11th Feb 20257:00 amRNSAIM Admission - Update
10th Feb 20257:00 amRNSAGM Statement
31st Jan 202512:41 pmRNSAnnual Financial Report
31st Jan 202512:31 pmRNSAnnual Financial Report
21st Jan 20257:00 amRNSBSF Enterprise and Sartorius
27th Dec 20247:00 amRNSAdmission of Placing Shares
18th Dec 20247:00 amRNS3DBT Ltd Secures Prestigious Northern Accelerator

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.